drugset / Trial / NCT04156269
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
Phase 0
Unknown
12 enrolled
iCell Gene Therapeutics
Chengdu Military General Hospital · collabPeking University Shenzhen Hospital · collabiCAR Bio Therapeutics Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.
Timeline
- Start
- 2018-08-31
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA-CS1 cCAR T cells | Cell therapy | — | Intravenous |